Skip to main content
Industry News
FDA drafts guidance for breast cancer drug studies

Draft guidance from the FDA says menopausal status should not be a basis for exclusion from clinical trials of breast cancer treatments and suggests ways for sponsors to include premenopausal women in studies of hormonal drugs and biological products. The FDA is accepting comments on the guidance.

Full Story: